<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02528071</url>
  </required_header>
  <id_info>
    <org_study_id>1308188</org_study_id>
    <secondary_id>2014-A00309-38</secondary_id>
    <nct_id>NCT02528071</nct_id>
  </id_info>
  <brief_title>Prognostic Value of a Diaphragmatic Endurance Test in Patients With Amyotrophic Lateral Sclerosis</brief_title>
  <acronym>SLA</acronym>
  <official_title>Prognostic Value of a Diaphragmatic Endurance Test in Patients With Amyotrophic Lateral Sclerosis : Impact and Prognosis. Single-center Prospective Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease which involves respiratory
      muscles and can lead at short term to respiratory failure. The occurrence of respiratory
      failure is associated with morbidity and an increased mortality. To date, respiratory muscle
      weakness is predicted from the reduction of vital capacity, maximal inspiratory force,
      nocturnal symptoms and hypercapnia. Even taken together, the predictive value of these
      indices is low.

      The investigators hypothesize that an endurance test of diaphragmatic work would be more
      sensitive to respiratory muscle involvement than maximal respiratory force.

      Consequently, the investigators assessed diaphragmatic performance through an isocapnic
      hyperventilation test (IHT) in patients at the onset of ALS and, then regularly up to the
      occurrence of respiratory failure. The investigators make the hypothesis that IHT will be
      altered earlier than maximal inspiratory force
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 29, 2014</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Endurance time</measure>
    <time_frame>Day 1</time_frame>
    <description>Difference in endurance time during the IHT between healthy controls and ALS patients when diagnosis is established</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reference values of the diaphragmatic endurance test</measure>
    <time_frame>Day 1</time_frame>
    <description>Reference values of the diaphragmatic endurance test in healthy controls according to age, by 10 years range.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reference values of phrenic nerve activity</measure>
    <time_frame>Day 1</time_frame>
    <description>Reference values of phrenic nerve activity in healthy controls according to age. It is measured with diaphragmatic Electromyogram by cervical electrical stimulation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Slope of endurance time decrease</measure>
    <time_frame>At Day 1 and every 3 months of follow-up (3 years)</time_frame>
    <description>Slope of endurance time decrease with time in ALS patients measured during IHT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amplitude of phrenic nerve</measure>
    <time_frame>At Day 1 and every 3 months of follow-up (3 years)</time_frame>
    <description>It is the relationship between phrenic nerve activity and diaphragmatic endurance in ALS patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Latency of phrenic nerve</measure>
    <time_frame>At Day 1 and every 3 months of follow-up (3 years)</time_frame>
    <description>It is the relationship between phrenic nerve activity and diaphragmatic endurance in ALS patients</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">165</enrollment>
  <condition>ALS (Amyotrophic Lateral Sclerosis)</condition>
  <arm_group>
    <arm_group_label>Patients</arm_group_label>
    <description>ALS patients performing measurements of maximal respiratory forces, diaphragmatic endurance during a diaphragmatic endurance test and phrenic nerve activity at the onset of the disease and repeated every 3 months up to respiratory failure or death</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Healthy controls performing measurements of maximal respiratory forces, diaphragmatic endurance during a diaphragmatic endurance test and phrenic nerve activity. This arm will enable to establish reference values of IHT</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Diaphragmatic endurance test</intervention_name>
    <description>This consists of hyperventilation in a flask while maintaining the constant level of Carbon Dioxide (CO2). The patient will realize hyperventilation to increasing levels of Maximum Minute Ventilation (MMV), corresponding to increasing levels of respiratory rate, until exhaustion</description>
    <arm_group_label>Patients</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with ALS Healthly volonteers
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria for Patients :

          -  Older than 18 years old and younger than 80 years old

          -  ALS patient seen during the diagnostic assessment

        Inclusion Criteria for control group :

          -  Older than 25 years old and younger than 80 years old

          -  No respiratory or neurologic active pathology

        Exclusion Criteria for Patients :

          -  Bulbar ALS (inability to perform maximal respiratory maneuvers)

          -  Dementia

          -  Respiratory failure at diagnosis (arterial carbon dioxide partial pressure (pCO2) &gt; 45
             mmHg)

          -  Respiratory or neurologic active pathology

        Exclusion Criteria for control group :

          -  Chest wall deformation with spirometric defect
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frederic COSTES, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>CHU de CLERMONT-FERRAND</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Isabelle COURT-FORTUNE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Saint-Etienne</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Isabelle COURT-FORTUNE, MD</last_name>
    <phone>(0)477828314</phone>
    <phone_ext>+33</phone_ext>
    <email>isabelle.court-fortune@chu-st-etienne.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Arnauld GARCIN, CRA</last_name>
    <phone>(0)477120286</phone>
    <phone_ext>+33</phone_ext>
    <email>arnauld.garcin@chu-st-etienne.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU de SAINT-ETIENNE</name>
      <address>
        <city>Saint-etienne</city>
        <zip>42000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Isabelle COURT-FORTUNE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Christophe ANTOINE, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Philippe CAMDESSANCHE, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Claude BARTHELEMY, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 18, 2015</study_first_submitted>
  <study_first_submitted_qc>August 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2015</study_first_posted>
  <last_update_submitted>October 26, 2017</last_update_submitted>
  <last_update_submitted_qc>October 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Amyotrophic Lateral Sclerosis</keyword>
  <keyword>ALS</keyword>
  <keyword>Diaphragmatic Endurance Test</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

